Lung Cancer News and Research

Latest Lung Cancer News and Research

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Crocus plant to provide a tumor killing “smart bomb”

According to the latest research, a drug derived from plant extracts could wipe out tumors in a single treatment with minimal side effects. Scientists have turned a chemical found in crocuses into a ‘smart bomb’ that targets cancerous tumors. The advantage is that healthy tissue is unharmed, reducing the odds of debilitating side effects. And unlike other side effect-free drugs, it is able to kill off more than one type of the disease, including breast, prostate, lung and bowel cancer. Potentially, all solid tumours could be vulnerable to drugs developed this way, meaning it could be used against all but blood cancers.

12 Sep 2011

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

A new study finds that lung cancer patients treated in hospitals that care for a high percentage of uninsured and Medicaid-insured patients, so-called "high safety-net burden facilities," were significantly less likely to undergo surgery that was intended to cure the cancer compared to patients treated at low safety-net burden facilities.

12 Sep 2011

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor.

9 Sep 2011

Individuals with excess BMI more likely to develop type 2 diabetes

Obesity is a known risk factor for developing type 2 diabetes. But it hasn't been clear whether the "dose" of obesity—how much excess weight a person has, and for how long—affects the risk of diabetes.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

U.S. smoking rates on slow decline: CDC report

Roughly 45 million adult Americans smoke and this is much lesser than the figures a few years back. Even those who still smoke have cut back on the number of cigarettes they smoke, but the rate of decline has begun to slow, U.S. health experts said on Tuesday. Smoking and exposure to secondhand smoke is the leading cause of preventable death and disease in the United States, killing an estimated 443,000 Americans each year.

6 Sep 2011

New genetic screening program for families at high risk of colorectal cancer

UT Southwestern Medical Center has developed a new lifesaving genetic screening program for families at high risk of contracting colorectal cancer, a deadly yet highly preventable form of cancer.

2 Sep 2011

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) responded significantly better to pemetrexed than patients whose cancer did not show ALK translocation, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

RI Hospital researcher supports use of ablation procedures for treatment of lung cancer

The journal Radiology will publish in its September issue an article written by Damian E. Dupuy, M.D., director of tumor ablation at Rhode Island Hospital, supporting the use of ablation procedures for the treatment of lung cancer.

2 Sep 2011

FDA approves crizotinib for treatment of ALK-positive lung cancer

In a major triumph for personalized medicine, the FDA approved the drug crizotinib for use with the lung cancer type known as ALK-positive.

2 Sep 2011

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

The nature of the connective tissue surrounding lung cancer nests can help predict the aggressiveness of squamous cell carcinoma, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.

2 Sep 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.

30 Aug 2011

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Pfizer Inc. has received FDA approval of XALKORI (crizotinib) capsules - the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

29 Aug 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Crocus plant to provide a tumor killing “smart bomb”

Lung cancer patients treated in high safety-net burden facilities less likely to undergo surgery

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Individuals with excess BMI more likely to develop type 2 diabetes

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

U.S. smoking rates on slow decline: CDC report

New genetic screening program for families at high risk of colorectal cancer

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

RI Hospital researcher supports use of ablation procedures for treatment of lung cancer

FDA approves crizotinib for treatment of ALK-positive lung cancer

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

LCA applauds FDA approval of Xalkori for ALK positive non-small cell lung cancer

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Pfizer receives FDA approval of XALKORI for ALK-positive NSCLC

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

The ultimate guide to lung research tools and protocols eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in